savolitinib + rifampicin

Savolitinib + rifampicin is a non-standard drug combination, not a marketed co-formulation, but refers to the co-administration of **savolitinib** and **rifampicin** for clinical or research purposes. - **Savolitinib** is a highly selective small molecule inhibitor of the mesenchymal epithelial transition factor (**MET**) tyrosine kinase, developed primarily for the treatment of non-small cell lung cancer (NSCLC) with MET alterations and being investigated in other solid tumors including gastric and renal cancers. - **Rifampicin** is a well-known antibiotic in the rifamycin class, most commonly used for tuberculosis and other bacterial infections, acting by inhibiting the DNA-dependent RNA polymerase in bacterial cells. This combination is not intended for routine clinical use; rather, interaction studies have shown rifampicin, a strong inducer of cytochrome P450 enzymes (notably CYP3A4), can significantly decrease savolitinib exposure by enhancing its metabolism[1].

Other names

rifampin